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Background: Afatinib has demonstrated efficacy in EGFR mutationpositive (EGFRm+) NSCLC; however, resistance develops over time, most commonly due to the emergence of the T790M mutation. Osimertinib has shown clinical activity in the treatment of T790M-positive disease following progression on a first-line tyrosine kinase inhibitor. Further information on outcomes of sequencing options is necessary to optimize treatment outcomes for patients. Method: This observational study is the first to evaluate outcomes of real-world patients who sequentially received first-line afatinib followed by osimertinib. Data were retrospectively collected between December 2017 and May 2018. Patients had common EGFRm+ (Del19, L858R) advanced NSCLC and acquired T790M after first-line afatinib. Patients must have completed afatinib treatment and started osimertinib treatment 10 months prior to data entry. Patients with active brain metastases were excluded. The primary outcome was time on treatment (ToT) from initiation of afatinib until discontinuation of osimertinib. Results: A total of 204 patients were included in the study; of these, 24.5/67.6% were Asian and non-Asian (Caucasian and African American), 15.3% had ECOG performance status 2, and 73.5/26.0% were Del19/L858R-positive. Overall median ToT was 27.6 months (90% CI: 25.9e31.3). Median time on afatinib and osimertinib was 11.9 months (90% CI: 10.9e12.2) and 14.3 months (90% CI: 12.8e15.9), respectively. The 2-year OS rate was 78.9%. ToT was generally consistent across patient subgroups; however, ToT was longer in Asian patients (n¼50; median 46.7 months; 90% CI: 26.8enot reached) and in those with Del19-positive disease (n¼150; median 30.3 months; 90% CI: 27.6e44.5). Patients with poor prognosis, such as those with ECOG PS 2 (n¼31, median ToT 22.2 months; 90% CI: 16.0e27.0) and stable brain metastases (n¼21, median ToT 19.4 months; 90% CI: 16.0enot reached), also appeared to derive clinical benefit. 6.6% of patients developed brain metastases on afatinib therapy. Conclusion: First-line afatinib followed by osimertinib is a feasible therapeutic strategy in a broad, real-world patient population with EGFRm+ NSCLC and acquired T790M mutation, resulting in 27.6 months of chemotherapy-free treatment. The benefit of sequential afatinib followed by osimertinib was observed across patient subgroups, with prolonged benefit seen in some subgroups, including those with Del19-positive disease. Thoracic Oncology, National Cancer Center Hospital, Chuo, Tokyo/JP Background: Patients with EGFR-mutation-positive non-small-cell lung cancer (EGFR-NSCLC) who are treated with both cytotoxic chemotherapy and EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have better survival outcomes than those who are only treated with EGFRTKIs. Limited information is available about the factors that influence the non-administration of cytotoxic chemotherapies after the failure of EGFR-TKIs. Method: We reviewed the medical records of EGFR-NSCLC patients who received EGFR-TKIs as a first-line treatment at the National Cancer Center Hospital between January 2010 and December 2016. Computed tomography data regarding the number of metastatic organs, at the time of progressive disease (PD), which reflects the tumor burden, was retrieved. EGFR-TKIs use beyond PD was also investigated. We performed a multivariate logistic regression analysis to determine the factors influencing the non-administration of cytotoxic chemotherapies. Results: A total of 393 patients received EGFR-TKIs as a first-line treatment during the study period. After the exclusion of 96 patients who were receiving ongoing EGFR-TKIs treatment, 297 patients (103 men, 194 women) were included in this analysis. The median age was 68 years (range, 33-87 years), and 291 patients had an adenocarcinoma histology; 155 had deletions in exon 19, 132 had the L858R point mutation in exon 21, and 10 had other minor mutations. An Eastern Cooperative Oncology Group performance status (PS) of 0e1, 2e4, and unknown was seen in 224, 55, and 18 patients, respectively. One-hundred and eleven patients received continued EGFR-TKIs treatment beyond PD. The number of metastatic organs at PD was evaluated, and 103 had 3 metastatic organs. Among the 297 patients included in this analysis, 177 (60%) received chemotherapy after EGFR-TKIs. A logistic regression analysis revealed that an age 70 years, a PS 2, the EGFR L858R mutation in exon 21, EGFR-TKIs use beyond PD, and 3 metastatic organs were independent factors influencing the non-administration of cytotoxic chemotherapies. Conclusion: EGFR-TKI use beyond progression, an increased number of metastatic organs, a higher age, and PS at the point of TKI failure were associated with the non-administration of subsequent cytotoxic chemotherapies.
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